Compassionate care is achieved when we combine our medical expertise with an unwavering responsibility, to treat others as we would want to be treated ourselves. The most fulfilling part of my day is found in the relationships that I build with my patients. I find it a privilege to be part of each and every patient's journey.
Medical Oncology, Hematology and Internal Medicine
Walter Reed National Military Medical Center (National Capital Consortium)
Dwight David Eisenhower Army Medical Center
Dwight David Eisenhower Army Medical Center
Lake Erie College of Osteopathic Medicine
University at Buffalo
Management of All Cancers, with a special interest in Lung Cancer and Thoracic Oncology
Dr. Brzezniak is originally from upstate New York and attended the University at Buffalo. She went onto earn her medical degree from Lake Erie College of Osteopathic Medicine. She then joined the Army, completing her internal medical training at Dwight David Eisenhower Army Medical Center and fellowship through the John P. Murtha Cancer Center at Walter Reed National Military Medical Center. Her military career spans 11 years, stationed not only in the United States but in support of deployed troops overseas. She served as the Assistant Chief Hematology Oncology clinic at Water Reed National Military Medical Center and is board certified in Medical Oncology, Hematology, and Internal Medicine. She is an accomplished Oncologist in management of all malignancies, and offers a warm collaborative approach to the complex care of her patients. She has a special interest in immunotherapy and lung cancer as well as breast cancer and other malignancies.
Dr. Brzezniak takes great pride in caring for her patients with cutting edge and compassionate community care. She has been recognized as a Top Doctor in Northern Virginia Magazine. While serving in the Army, she was named as the Chief of Immuno-Oncology and Thoracic Oncology, helping to build the research program at the John P. Murtha Cancer Center. At Virginia Cancer Specialists, she also serves as the principal investigator on multiple lung cancer clinical trials. She is a member of the American Society of Clinical Oncology and a national clinical trials researcher. She has contributed to multiple research publications on lung cancer and other types of malignancies. In an effort to help eliminate barriers for the management of lung cancer in our community, Dr. Brzezniak has been asked to participate as a panel representative for the FDA.
Dr. Brzezniak is affiliated with HCA Reston Hospital and INOVA Loudoun Hospital.
Dr. Brzezniak enjoys spending time with her husband and three children and her dog, Max. Her leisure time is spent reading, drawing and baking.
Recalcitrant small cell lung cancer: the argument for optimism.Read More
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.Read More
Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.Read More
RRx-001 protects against cisplatin-induced toxicities.Read More
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.Read More
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.Read More
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.Read More
Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma.Read More
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.Read More
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.Read More
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.Read More
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.Read More
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.Read More
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02)
Randomized, Open-Label Phase III Study of SAR408701 Versus Docetaxel in Previous Treated Mets Non-Squamous NSCLC Patients with CEACAM5 Positive Tumors
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)